Health and Healthcare

Monday's Top Biotech and Medical Stocks

From BioHealth Investor

Biotechnology

POLYMEDIX INC [PYMX.OB] +60.00%
SEATTLE GENETICS I [SGEN] +24.01%
CYCLACEL PHARMACEUTI [CYCC] +20.93%
INNCARDIO INC [ICDO.OB] +19.05%
PIPEX PHARMACEUTICAL [PPXP.OB] +12.78%

Diagnostic Substances

IMMUNOMEDICS INC [IMMU] +16.85%
ICAGEN, INC. [ICGN] +13.57%
GENE LOGIC INC [GLGC] +4.24%
CYTOGEN CORP [CYTO] +3.70%
PONIARD PHARMA [PARD] +3.39%

Drug Delivery

QUIGLEY CORP THE [QGLY] +11.39%
DELCATH SYSTEMS INC [DCTH] +4.23%
FLAMEL TECH SA ADR [FLML] +2.23%
ALKERMES INC [ALKS] +1.62%
INSITE VISION INC [ISV] +1.36%

Drug Manufacturers

CORTEX PHARM INC [COR] +6.39%
PROVECTUS PHARMA [PVCT.OB] +5.88%
JAVELIN PHARMACEUTIC [JAV] +4.49%
DEPOMED INC [DEPO] +4.43%
NEUROCHEM INC [NRMX] +4.00%

Medical Appliances & Equipment

SIGNALIFE INC [SGN] +35.85%
CELSION CORP [CLN] +23.93%
INTRALASE CORP. [ILSE] +10.26%
EMERGENT GROUP INC [EMGP.OB] +7.43%
EDAP TMS SA ADR [EDAP] +6.91%

Medical Instruments & Supplies

ANGEION CORP [ANGN] +8.23%
OSTEOTECH INC [OSTE] +7.35%
ADVANCED MED OPTICS [EYE] +4.77%
ANTARES PHARMA INC [AIS] +4.17%
BOSTON SCIENTIFIC CP [BSX] +4.15%

Medical Laboratories & Research

AASTROM BIOSCIENCE [ASTM] +8.90%
PREMD INC [PME] +5.63%
GENOMIC HEALTH, INC. [GHDX] +4.59%
NEOGENOMICS INC [NGNM.OB] +3.27%
ALLIANCE IMAGING INC [AIQ] +3.14%

http://www.biohealthinvestor.com/

Smart Investors Are Quietly Loading Up on These “Dividend Legends”

If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats. There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside. If you’re tired of feeling one step behind in this market, this free report is a must-read for you.

Click here to download your FREE copy of “2 Dividend Legends to Hold Forever” and start improving your portfolio today.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.